Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors
Applying the modified Response Evaluation Criteria in Solid Tumors (mRECIST), we observed that patients with higher intracellular GSH levels responded worse to neoadjuvant chemotherapy, as indicated by MRI scans, than those with lower intracellular GSH levels (Fig
PMID 34815532
This sample shows a relevant deviation between the GHS/MGT ratio between ICP measurement and proposed model prediction
Gastrointestinal symptoms including nausea, vomiting, diarrhea, constipation, and abdominal discomfortare the most frequently reported adverse effects, occurring in 20-30% of patients (varying by dose and population), particularly during dose escalation
The US GLP-1 user population is large and growing, and current government policy and drug-provider pricing strategies are breaking down adoption barriers and may make it grow faster, said Rick Miller, partner and marketing effectiveness practice lead at Big Chalk
